Novo Holdings backs animal health company Invetx

Novo Holdings today announces it has participated in a $60.5 million oversubscribed Series B financing in Boston-based Invetx, a pioneer in protein-based therapeutics for companion animal health.

The financing allows the Company to advance its monoclonal antibody (mAb) pipeline and pursue market approvals for therapeutics targeting chronic and serious diseases in dogs and cats.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH